***TASK***
the task is to simplify the input abstract of a biomedical literature

***INPUT***
the input is the abstract of a biomedical literature

***OUTPUT***
the output is the simplified abstract for the input abstract of a biomedical literature

***DOCUMENTATION***

***EXAMPLES***

Input: Thirty seven studies (2185 participants) were included in this review. There was no significant difference in the risk for CMV disease (16 studies, 770 patients: RR 0.80, 95% CI 0.61 to 1.05), CMV infection (14 studies, 775 patients: RR 0.94, 95% CI 0.80 to 1.10) or all-cause mortality (8 studies, 502 patients: RR 0.57, 95% CI 0.32 to 1.03) with IgG compared with placebo/no treatment. However IgG significantly reduced the risk of death from CMV disease (6 studies, 346 patients: RR 0.33, 95% CI 0.14 to 0.80). There was no difference in the risk for CMV disease (4 studies, 298 patients: RR 1.17, 95% CI 0.74 to 1.86), CMV infection (4 studies, 298 patients: RR 1.16, 95% CI 0.89 to 1.52) or all-cause mortality (2 studies, 217 patients: RR 0.92, 95% CI 0.37 to 2.29) between antiviral medication combined with IgG and antiviral medication alone. There was no significant difference in the risk of CMV disease with anti CMV vaccine or interferon compared with placebo or no treatment. Currently there are no indications for IgG in the prophylaxis of CMV disease in recipients of solid organ transplants.
Output:

This review looked at the benefits and harms of IgG, anti CMV vaccines and interferon to prevent CMV disease in solid organ transplant recipients. Thirty seven studies (2185 participants) were identified. This review shows that IgG did not reduce the risk of CMV disease or all-cause mortality compared with placebo or no treatment. The combination of IgG with antiviral medications (aciclovir or ganciclovir) were not more effective than antiviral medications alone in reducing the risk of CMV disease or all-cause mortality. Anti CMV vaccines and interferon did not reduce the risk of CMV disease compared with placebo or no treatment. Currently there are no indications for IgG in the prevention of CMV disease in recipients of solid organ transplants.